Compass Pathways PLC ADR CMPS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights
New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers
Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress
Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026
Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $8.60
- Day Range
- $7.78–8.61
- 52-Week Range
- $4.88–15.87
- Bid/Ask
- $7.75 / $7.80
- Shares Outstanding
- 141.71M
- Market Cap
- $1.11B
- Volume/Avg
- 6M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Stock Style Box
- —
- Total Number of Employees
- 156
- Website
- https://compasspathways.com
Valuation
Metric | CMPS |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.79 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | CMPS |
|---|---|
Quick Ratio | 1.41 |
Current Ratio | 1.50 |
Interest Coverage | −49.25 |
Quick Ratio
CMPS
Profitability
Metric | CMPS |
|---|---|
Return on Assets (Normalized) | −44.91% |
Return on Equity (Normalized) | −168.72% |
Return on Invested Capital (Normalized) | −121.31% |
Return on Assets
CMPS
Medical Care Facilities Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| HCA Healthcare Inc HCA | LOCK|>CYj$K | LOCK|$TzKj | $106B | |||
| Fresenius SE & Co KGaA ADR FSNUY | — | LOCK|SLt## | $32B | |||
| Fresenius SE & Co KGaA Registered Shares FSNUF | — | LOCK|Z$#k> | $32B | |||
| Tenet Healthcare Corp THC | LOCK|$Q><Fb@ | LOCK|?p$R | $23B | |||
| Encompass Health Corp EHC | — | LOCK|BsK? | $14B | |||
| DaVita Inc DVA | LOCK|MYJH^vJ | LOCK|M%r@ | $12B | |||
| Fresenius Medical Care AG FMCQF | — | LOCK|N#Zl | $12B | |||
| Fresenius Medical Care AG ADR FMS | LOCK|rwd&^W& | LOCK|@w%V^ | $12B | |||
| Universal Health Services Inc Class B UHS | LOCK|VL@S!Q | LOCK|NVmh | $12B | |||
| Ensign Group Inc ENSG | — | LOCK|#swb | $11B |
United States